Intellia Therapeutics (NTLA) Misses Q1 EPS by 86c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.96), $0.86 worse than the analyst estimate of ($1.10). Revenue for the quarter came in at $0 versus the consensus estimate of $8.54 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS